Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2017-05-18 AGM Information
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled 'KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)' which translates to 'COMMUNIQUÉ FROM THE ANNUAL GENERAL MEETING OF ONCOPEPTIDES AB (PUBL)'. The text details the main decisions made at the 2017 AGM, including the approval of the annual report, election of board members, and decisions regarding remuneration guidelines and incentive programs (LTIPs). This content directly relates to the proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2017-05-18 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Kvartalsrapport januari - mars 2017' (Quarterly Report January - March 2017) and contains comprehensive financial statements, including income statements, cash flow data, and management commentary for the first quarter of 2017. It provides actual financial performance metrics rather than just an announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. Q1 2017
2017-05-18 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report January - March 2017' and contains comprehensive financial data, including a summary of Q1, a financial overview of the group, and a CEO statement. It covers a period shorter than a full fiscal year (Q1 2017) and provides substantive financial analysis and statements, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-18 English
Ändring av antalet aktier och röster i Oncopeptides AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement dated April 28, 2017, detailing an increase in the number of shares and votes due to the exercise of an over-allotment option following a stock market listing. The key phrases are 'Ändring av antalet aktier och röster' (Change in the number of shares and votes) and the final count of shares. This directly relates to a change in the company's capital structure or share count. This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers changes in share count, even if resulting from an option exercise related to a prior listing event. It is not a dividend notice (DIV), a director's dealing (DIRS), or a general regulatory filing (RNS) as it is highly specific to capital structure.
2017-04-28 Swedish
Change in number of shares and votes in Oncopeptides AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly announces a 'Change in number of shares and votes in Oncopeptides AB (publ)' due to the 'new issue of shares that was made in connection with the exercise of the over-allotment option'. This directly relates to changes in the company's capital structure, specifically the total number of outstanding shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document is a formal announcement regarding a change in share count, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the substantive information itself.
2017-04-28 English
ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)" and details the notice, agenda, proposed resolutions, and specific proposals regarding director elections, fees, and incentive programs to be voted upon at this meeting. The content is characteristic of the materials distributed to shareholders in advance of an Annual General Meeting (AGM). While it contains elements that might appear in other reports (like the mention of the annual report under item 8), the primary purpose and structure are to convene and inform shareholders for the AGM. This aligns perfectly with the definition of AGM Information (AGM-R). It is not a proxy statement (PSI) as it is the notice/agenda itself, nor is it the full Annual Report (10-K).
2017-04-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.